These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16524647)

  • 1. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
    Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
    Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope.
    Fayolle C; Davi M; Dong H; Ritzel D; Le Page A; Knipping F; Majlessi L; Ladant D; Leclerc C
    Vaccine; 2010 Oct; 28(42):6930-41. PubMed ID: 20728521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
    Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
    Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
    Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C
    Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization.
    Partidos CD; Hoebeke J; Moreau E; Chaloin O; Tunis M; Belliard G; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2005 May; 35(5):1521-9. PubMed ID: 15789358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
    Ensoli B; Cafaro A
    J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocytes deliver Tat to interferon-gamma-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro.
    Corinti S; Chiarantini L; Dominici S; Laguardia ME; Magnani M; Girolomoni G
    J Leukoc Biol; 2002 Apr; 71(4):652-8. PubMed ID: 11927652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
    Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
    Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
    Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
    Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach.
    Karasev AV; Foulke S; Wellens C; Rich A; Shon KJ; Zwierzynski I; Hone D; Koprowski H; Reitz M
    Vaccine; 2005 Mar; 23(15):1875-80. PubMed ID: 15734059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
    Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
    Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
    Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
    Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.